Our Leadership Team
Peter Staehr, MD
Interim Chief Medical Officer Peter Staehr, MD, is a senior executive medical doctor with 20+ years of global clinical development experience and executive management in Pharmaceutical/Biotech as well as Medical Drug-Device combination. He was trained as internist and cardiologist at Johannes-Gutenberg University Mainz, Germany, and completed his postdoc fellowship at Stanford University. Dr. Staehr held leadership roles in early- and late-stage (Phase 1-3) clinical development with increasing responsibilities at small to large-size organizations (J&J, Theravance, CV Therapeutics, Gilead, Abbott Vascular, ChemoCentryx). As the medical lead he oversaw numerous IND drug development programs in various therapeutic areas and was directly involved in the registration of Regadenoson (Lexiscan®) and Abbott’s Absorb™ bioresorbable stent. Dr. Staehr is the consulting CMO of two companies including Renexxion. He also serves as the chairman of the San Francisco Bay Area chapter of the Pharmaceutical & BioScience Society (PBSS).
|